The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 333:1285-1286 November 9, 1995 Number 19
NextNext

Interferon Alfa and Zidovudine in Adult T-Cell Leukemia–Lymphoma

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
 by Gill, P. S.
-PubMed Citation
To the Editor: Gill et al. (June 29 issue)1 report the encouraging results of a trial in which interferon alfa and zidovudine were combined for the treatment of adult T-cell leukemia–lymphoma. The response to this treatment was impressive, and the toxicity levels were acceptable. These results may be a blessing for patients with adult T-cell leukemia–lymphoma in Japan, where more than 700 new cases are diagnosed each year among the 1.2 million carriers of the human T-cell lymphotropic virus type I.2 However, two points are not clear.

First, is the combination of interferon alfa and zidovudine essential? It has already . . . [Full Text of this Article]

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.